NCT02306161
Clinical Trial Information
Trial Number: NCT02306161 (ClinicalTrials.gov)
Disease Type:
- Miscellaneous Neoplasm - Metastases, Distant (excluding specified site of origin)
Trial Title:
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Study ID:
AEWS1221
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
Accessibility | Disclaimer | FOIA | HHS Vulnerability Disclosure | Privacy & Security
U.S. Department of Health and Human Services | National Institutes of Health | National Cancer Institute | USA.gov
NIH…Turning Discovery Into Health®